retatrutide triple agonist gip glp-1 glucagon phase 3 2025 What GLP‑3 Really Is: Triple‑Receptor Drug Diagram showing the mechanism of

Based on a comprehensive analysis of the relevant literature, due to the extensive distribution of GLP-1R, its expression has been detected on the surface of related endocrine glands such as the pancreas and digestive glands

Isaac Glatstein, MD, MSc, at Conceive NJ.

In adults with overweight or obesity (without diabetes) the semaglutide 2.4 mg dose produced an average weight reduction of about 15% of baseline body weight over ~68 weeks in the STEP 1 trial, a result that surprised many clinicians because it brought pharmacologic outcomes into a range previously associated with surgical interventions

The recent December 2025 phase 3 trial showed even better results

Prevention: Every time you start a new vial, check the concentration on the label

Effect on Energy Metabolism The sort of thing I love is how semaglutide changes energy metabolism